CD274 and cancer: After categorizing the cancer patients based on the optimal cutoff value of CAGS, those with a high CAGS exhibited a clinical benefit in both the anti‐PD‐1 (GSE78220, Fig. 3A,B) and anti‐PD‐L1 (IMvigor210, Fig. 3C,D) ICB therapy cohorts.